Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | LDHB | P07195 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094833 | 1.00 | GAA (0.46) | GAASRPK1ALDH1A1KCNQ2SMN1; SMN2 | |
| SCHEMBL31576842 | 0.77 | KCNQ2 (0.58) | SRPK1ALDH1A1KCNQ2SMN1; SMN2KCNQ3 | |
| SCHEMBL22288452 | 0.76 | KCNQ3 (0.59) | KCNQ2KCNQ3LMNAHPGD | |
| SCHEMBL22288483 | 0.76 | KCNQ2 (0.57) | SRPK1ALDH1A1KCNQ2SMN1; SMN2KCNQ3 | |
| SCHEMBL3101145 | 0.75 | KCNQ2 (0.50) | KCNQ2KCNQ3MAPTL3MBTL1 | |
| SCHEMBL30795469 | 0.75 | KCNQ2 (0.50) | KCNQ2KCNQ3MAPTL3MBTL1 | |
| SCHEMBL14271378 | 0.73 | MAPT (0.56) | ALDH1A1KCNQ2SMN1; SMN2LMNAMAPT | |
| SCHEMBL22299365 | 0.72 | KCNQ3 (0.62) | GAAKCNQ2KCNQ3LMNAMAPT | |
| SCHEMBL3596698 | 0.72 | PPARA (0.55) | ALDH1A1KCNQ2KCNQ3KDM4E | |
| SCHEMBL2070060 | 0.72 | POLB (0.57) | GAAALDH1A1LMNAL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |